Abstract: Provided is a method for sorting nucleated red blood cells in which fetus-derived nucleated red blood cells are sorted out from maternal blood. The method includes a nucleated red blood cell specification step of specifying nucleated red blood cells to be sorted out; a reference red blood cell selection step of setting a search range including the nucleated red blood cells and selecting red blood cells having no nucleus within the search range as reference red blood cells; and a sorting step of sorting the nucleated red blood cells into mother-derived nucleated red blood cells and fetus-derived nucleated red blood cells in accordance with spectral characteristics attributable to oxygen affinity of hemoglobin of the nucleated red blood cells and the reference red blood cells.

Abstract: A method for inspecting a chromosome of a fetus includes: a collection step of obtaining maternal blood from a pregnant mother; a concentration step of concentrating nucleated red blood cells in the maternal blood; a sorting step of sorting the nucleated red blood cells in the maternal blood, in which the nucleated red blood cells are concentrated through the concentration step, into mother-derived nucleated red blood cells and fetus-derived nucleated red blood cells in accordance with the shapes of nuclei and spectral characteristics at wavelengths included in a light wavelength region of 400 to 650 nm; an amplification step of amplifying a nucleic acid of a chromosome of the nucleated red blood cells; a definition step of defining an amount of the amplified product of the nucleated red blood cells; and a determination step of determining presence or absence of a numerical abnormality of the fetus-derived chromosome.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).

Abstract: A developing device including: a toner bearing member configured to bear a toner on a surface of the toner bearing member and configured such that the surface thereof is rotated to supply the toner to and develop a latent electrostatic image on a surface of a latent electrostatic image bearing member in a developing region which faces the latent electrostatic image bearing member; and a regulating member configured to regulate an amount of the toner to be moved towards the developing region, wherein the surface of the toner bearing member has regularly arranged convex portions, and wherein a non-electrostatic adhesive force between the toner and the surface of the toner bearing member is less than 9.0 nN.

Abstract: A development device includes a developer bearer to carry by rotation developer to a development range facing a latent image bearer, and a planar metal developer regulator to adjust an amount of developer carried by the developer bearer to the development range. The developer bearer includes a developer carrying range having surface unevenness, and the developer regulator includes a fixed end portion held by a regulator holder and a free end portion to contact a surface of the developer bearer.

Abstract: The purpose of the present invention is to create an immune tolerance-inducing agent used in therapy in which donor hematopoietic cells are transplanted into a recipient in order to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. By using an alpha-galactosylceramide-containing liposome in combination with a costimulatory-pathway-blocking substance, hematopoietic chimerism can be induced in the recipient by transplantation of donor hematopoietic cells, making it possible to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs.

Abstract: The purpose of the present invention is to provide a preparation for preventing or treating type I diabetes, said preparation exerting an excellent effect of preventing or treating type I diabetes, and a method for preventing or treating type I diabetes. The onset and symptoms of type I diabetes can be very remarkably relieved by dosing a combination of: (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof; with (B) ?-GalCer.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: A development device includes a developer bearer to carry by rotation developer to a development range facing a latent image bearer and a developer regulator to adjust an amount of developer transported to the development range by the developer bearer. The developer bearer includes a developer carrying range having surface unevenness; and a surface of the developer bearer is coated with a coating material including a resin material and particles to roughen the surface.

Abstract: An image forming apparatus includes a latent image carrier; a latent image writer to write a latent image on the latent image carrier; a developing unit including a toner carrier having first and second electrodes insulated via an insulator member and a voltage applying unit to apply voltages to the first and second electrodes having a potential difference to generate first electric fields to cause the toner to hop from the toner carrier to the latent image carrier to develop a toner image; and a transfer unit to transfer the developed toner image to a transferring member. When alternating voltages having a same phase and same amplitude are applied to the first and second electrodes to form second electric fields between the latent image carrier and the toner carrier, the toner is discharged from the toner carrier to the latent image carrier in a toner discharge mode.

Abstract: A development device includes a developer bearer to carry by rotation developer to a development range facing a latent image bearer, and a developer regulator to adjust an amount of developer transported to the development range by the developer bearer. Multiple projections are formed in a surface of the developer bearer, and, in a direction in which the developer bearer rotates, a downstream end of each of the multiple projections is higher than an upstream end of the projection.

Abstract: A liposome containing a regulatory cell ligand such as ?-galactosyl ceramide or ?-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.

Abstract: An image forming apparatus includes a latent image carrier to carry a latent image, a developing device having a toner carrier with first and second electrodes to develop the latent image by transferring the toner to a developing region between the toner carrier and the latent image carrier while causing the toner to hop between the first and second electrodes and attaching the hopping toner to the latent image, a pulsed power supply to output a first periodic pulse voltage having a mean potential the same as a normal toner charge and a second periodic pulse voltage, a smoothing circuit to make the first periodic pulse voltage smooth to generate a direct voltage, and a toner layer thickness regulator member to regulate, on receiving the direct voltage, a thickness of the toner layer in a region between a toner supply position at which toner is supplied and the developing region.

Abstract: A development device includes a developer container; a rotary cylindrical developer carrier including an outer electrode including multiple electrode portions arranged in a circumferential direction of the developer carrier, an inner electrode provided on an inner circumferential side of the developer carrier from the outer electrode, an insulation layer disposed between the outer electrode and the inner electrode, and a surface layer; and a bias power source to apply a first bias voltage and a second bias voltage to the inner electrode and the outer electrode, respectively. The first bias power source causes an electrical potential difference that changes with time between the inner electrode and the outer electrode to cause the developer to hop on a circumferential surface of the developer carrier. At least one of the first bias voltage and the second bias voltage has a cyclic waveform in which pulse-on time is reduced.

Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.

Abstract: A development device includes a developer container, a rotary developer carrier that is disposed facing the latent image carrier and including multiple outer electrodes arranged in a circumferential direction of the developer carrier, an inner electrode electrically insulated from the multiple outer electrodes, an insulation layer disposed between the inner and outer electrodes, and a surface layer overlaying the outer electrodes and electrically insulating the multiple outer electrodes from each other, a bias power source to generate electrical fields that change with time by applying a first and second bias voltages to the inner and outer electrodes, respectively, an electrical field adjuster to regulate the electrical fields in accordance with a thickness of the surface layer of the developer carrier, and a controller.

Abstract: Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).

Abstract: A development device includes a developer bearer to carry by rotation developer to a development range facing a latent image bearer, and a developer regulator to adjust an amount of developer transported to the development range by the developer bearer. Multiple projections are formed in a surface of the developer bearer, and, in a direction in which the developer bearer rotates, a downstream end of each of the multiple projections is higher than an upstream end of the projection.

Abstract: A development device includes a developer bearer to carry by rotation developer to a development range facing a latent image bearer and a developer regulator to adjust an amount of developer transported to the development range by the developer bearer. The developer bearer includes a developer carrying range having surface unevenness; and a surface of the developer bearer is coated with a coating material including a resin material and particles to roughen the surface.